Population Pharmacokinetics of Aplidin® (plitidepsin) in Subjects with Cancer .

en relacion :
http://www.page-meeting.org/?abstract=1204

El nuevo fondo Ysios invertirá 65 millones en biotecnología .

Aplidin y Analogos en Combi. , Patente Mundial Tratamiento Cancer Pulmon, MAMA , Colon, Prostata, Riñon , Melanoma , Myeloma , Leucemia y Lymphomas .

IMPROVED ANTITUMORAL TREATMENTS

Publication number: WO2007101235
Publication date: 2007-09-07
Inventor: FAIRCLOTH GLYNN THOMAS (US); AVILES MARIN PABLO MANUEL (ES); LEPAGE DOREEN (US); SAN MIGUEL IZQUIERDO JESUS (ES); PANDIELLA ATANASIO (ES)
Applicant: PHARMA MAR S A U (ES); FAIRCLOTH GLYNN THOMAS (US); AVILES MARIN PABLO MANUEL (ES); LEPAGE DOREEN (US); SAN MIGUEL IZQUIERDO JESUS (ES); PANDIELLA ATANASIO (ES)
Classification:
- international:
- European:
Application number: WO2007US62936 20070228
Priority number(s): US20060813606P 20060228


Abstract of WO2007101235

The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.

Dia Mundial del Alzheimer .

Nivel de BRCA influye en la evolución del cáncer de mama precoz .